Intranasal Fluticasone Propionate for Pediatric Allergic Rhinitis – Evidence‑Based Guideline Summary
1. Efficacy
- Intranasal corticosteroids are the most effective medication class for treating allergic rhinitis in children, outperforming oral antihistamines and leukotriene antagonists. (Strong evidence) 1, 2, 3
- Symptom improvement (nasal congestion, rhinorrhea, sneezing, itching) typically begins within 3–12 hours after the first dose. (Moderate evidence) 1, 3
2. Safety
- At the pediatric‑approved dose (≈ 100 µg daily), fluticasone propionate has an excellent safety profile with no clinically significant systemic effects. (Strong evidence) 1, 3, 4
- Studies show no suppression of the hypothalamic‑pituitary‑adrenal (HPA) axis at recommended doses. (Strong evidence) 1, 3
- Growth‑velocity studies of fluticasone propionate, mometasone, and budesonide demonstrate no impact on linear growth, even when doses are doubled. (Strong evidence) 1, 3
3. Administration Technique
- Correct spray technique is essential to maximize efficacy and minimize local adverse effects. (Strong evidence) 1, 2
- The spray should be directed laterally toward the outer nasal wall, avoiding the septum to prevent irritation or perforation. (Strong evidence) 1, 2
- A supervising adult should periodically inspect the nasal septum for rare mucosal erosions. (Moderate evidence) 1, 3
4. Adjunctive and Step‑Up Therapy
- If symptoms are inadequately controlled after 2–4 weeks of fluticasone monotherapy, add an intranasal antihistamine rather than increasing the corticosteroid dose. (Strong evidence) 5
- Combination therapy (intranasal corticosteroid + intranasal antihistamine) provides superior symptom control compared with either agent alone in moderate‑to‑severe disease. (Strong evidence) 5
- Adding an oral antihistamine to intranasal corticosteroids yields minimal additional benefit. (Moderate evidence) 2
5. Practices to Avoid
- Do not use over‑the‑counter cough/cold products containing first‑generation antihistamines and decongestants in young children; they have poor efficacy and safety concerns. (Strong evidence) 1, 3, 6
- Avoid topical nasal decongestants (e.g., oxymetazoline, phenylephrine) for more than 3 days to prevent rhinitis medicamentosa. (Strong evidence) 2
- Systemic corticosteroids should never be first‑line when an intranasal corticosteroid is appropriate. (Strong evidence) 1, 4